

# Clemens Grassberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4514335/publications.pdf>

Version: 2024-02-01

49  
papers

1,541  
citations

361045

20  
h-index

329751

37  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1674  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the interactions between radiotherapy and antitumour immunity. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 729-745.	12.5	183
2	Motion Interplay as a Function of Patient Parameters and Spot Size in Spot Scanning Proton Therapy for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 380-386.	0.4	168
3	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.4	99
4	Asymptomatic Late-phase Radiographic Changes Among Chest-Wall Patients Are Associated With a Proton RBE Exceeding 1.1. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 809-819.	0.4	84
5	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. <i>Neuro-Oncology</i> , 2021, 23, 284-294.	0.6	78
6	Assessing the Clinical Impact of Approximations in Analytical Dose Calculations for Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1157-1164.	0.4	75
7	Motion mitigation for lung cancer patients treated with active scanning proton therapy. <i>Medical Physics</i> , 2015, 42, 2462-2469.	1.6	74
8	Quantification of Proton Dose Calculation Accuracy in the Lung. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 424-430.	0.4	70
9	Roadmap: proton therapy physics and biology. <i>Physics in Medicine and Biology</i> , 2021, 66, 05RM01.	1.6	67
10	Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model. <i>Scientific Reports</i> , 2017, 7, 13542.	1.6	56
11	Challenges of radiotherapy: Report on the 4D treatment planning workshop 2013. <i>Physica Medica</i> , 2014, 30, 809-815.	0.4	32
12	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. <i>Cancer Research</i> , 2019, 79, 3776-3788.	0.4	32
13	Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1222-1225.	0.4	29
14	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 726-735.	0.4	29
15	Comparison of weekly and daily online adaptation for head and neck intensity-modulated proton therapy. <i>Physics in Medicine and Biology</i> , 2021, 66, 055023.	1.6	28
16	A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 151, 73-81.	0.3	26
17	4D blood flow model for dose calculation to circulating blood and lymphocytes. <i>Physics in Medicine and Biology</i> , 2020, 65, 055008.	1.6	25
18	Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. <i>Radiotherapy and Oncology</i> , 2022, 168, 1-7.	0.3	25

#	ARTICLE	IF	CITATIONS
19	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.4	24
20	Automated Monte Carlo Simulation of Proton Therapy Treatment Plans. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, NP35-NP46.	0.8	23
21	Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 986-995.	0.4	23
22	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	1.8	21
23	Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. <i>Npj Precision Oncology</i> , 2018, 2, 22.	2.3	20
24	HEDOSâ€”a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations. <i>Physics in Medicine and Biology</i> , 2021, 66, 164001.	1.6	20
25	Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1055-1062.	0.4	19
26	Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes. <i>Neuro-Oncology Practice</i> , 2016, 3, 173-187.	1.0	18
27	Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons. <i>Radiotherapy and Oncology</i> , 2019, 136, 169-175.	0.3	18
28	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i> -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	3.2	18
29	Varying relative biological effectiveness in proton therapy: knowledge gaps versus clinical significance. <i>Acta Oncologica</i> , 2017, 56, 761-762.	0.8	15
30	Four-dimensional Monte Carlo simulations demonstrating how the extent of intensity modulation impacts motion effects in proton therapy lung treatments. <i>Medical Physics</i> , 2013, 40, 121713.	1.6	14
31	Density overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors. <i>Physics in Medicine and Biology</i> , 2018, 63, 035023.	1.6	14
32	Considerations when treating lung cancer with passive scatter or active scanning proton therapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 210-215.	1.3	13
33	A dynamic blood flow model to compute absorbed dose to circulating blood and lymphocytes in liver external beam radiotherapy. <i>Physics in Medicine and Biology</i> , 2022, 67, 045010.	1.6	13
34	Fractionated Lung IMPT Treatments. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 689-696.	0.8	12
35	Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients. <i>International Journal of Particle Therapy</i> , 2021, 8, 17-27.	0.9	11
36	Biomathematical Optimization of Radiation Therapy in the Era of Targeted Agents. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 13-17.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Computing proton dose to irregularly moving targets. <i>Physics in Medicine and Biology</i> , 2014, 59, 4261-4273.	1.6	7
38	Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28558.	0.8	7
39	Modeling Resistance and Recurrence Patterns of Combined Targeted Chemoradiotherapy Predicts Benefit of Shorter Induction Period. <i>Cancer Research</i> , 2020, 80, 5121-5133.	0.4	7
40	Physics of Particle Beam and Hypofractionated Beam Delivery in NSCLC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 162-169.	1.0	6
41	Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1044-1052.	0.4	6
42	A mesh-based model of liver vasculature: implications for improved radiation dosimetry to liver parenchyma for radiopharmaceuticals. <i>EJNMMI Physics</i> , 2022, 9, 28.	1.3	6
43	Predicting Organ-Specific Risk Interactions between Radiation and Chemotherapy in Secondary Cancer Survivors. <i>Cancers</i> , 2017, 9, 119.	1.7	5
44	Pre- and post-treatment image-based dosimetry in <sup>90</sup> Y-microsphere radioembolization using the TOPAS Monte Carlo toolkit. <i>Physics in Medicine and Biology</i> , 2021, 66, 244002.	1.6	4
45	Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors. <i>Advances in Radiation Oncology</i> , 2022, 7, 100880.	0.6	3
46	Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. <i>Cancer Immunology Research</i> , 2022, 10, 1055-1068.	1.6	3
47	Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 6-12.	0.8	1
48	Modelling treatment-response rates. <i>Nature Biomedical Engineering</i> , 2021, 5, 295-296.	11.6	0
49	Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100169.	1.0	0